Navigation Links
RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments
Date:3/26/2015

ROCKVILLE, Md., March 26, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx") today announced that it has received a patent acceptance notice from the Israeli patent office with claims for administering Thymosin beta 4 (TB4) to prevent or reduce tissue damage caused by an increase in blood flow, as is often the case when cardiac vessels are opened after a blockage causing a heart attack or in similar circumstances when treating stroke victims.

Damage can be caused to the heart attack or stroke patient when doctors open the vessel to restore blood flow to the tissue.  This increased blood flow is commonly attained using medical devices such as stents, drugs known as "clot busters," and by cardiac bypass and neuro surgeries.  However, the rapid onrush of oxygen-rich blood to the damaged tissue can cause a phenomenon known as "reperfusion injury," which further damages the tissue by causing sudden inflammation, destroying cell membranes and DNA, and by releasing free radicals.  TB4 has been shown in numerous scientific publications to prevent, reduce and/or repair such damage.  The subject patent includes claims using Thymosin beta 4, its various fragments and analogues, and expires in 2026.

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the U.S., and has an extensive worldwide patent portfolio covering its products. RGN-259, the Company's TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary focus of RegeneRx's clinical development efforts in the U.S.  RegeneRx was recently allowed by the FDA to move into Phase III clinical trials with RGN-259 for the treatment of patients with NK.  RGN-352, the Company's TB4-based injectable, is a Phase 2-ready drug candidate designed to be administered systemically to prevent and restore tissue damage associated with acute events such as heart attacks, strokes, and other similar traumatic injuries.  For additional information about RegeneRx please visit www.regenerx.com.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.  There can be no assurance that any issued patents or licenses held by the Company or patent applications filed by the Company in the U.S. or any other country will result in future value.  There can also be no assurance that any of the Company's drug candidates will result in any approved products in the U.S. or any other country.  Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.


'/>"/>
SOURCE RegeneRx Biopharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. RegeneRx Releases Letter to Shareholders
2. RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage
3. RegeneRx Joint Venture Partner Receives $7.28 million USD From Korean Government and Venture Fund for U.S. Development of RGN-259/GBT-201
4. IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit
5. Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System
8. BioElectronics Receives Working Capital Infusion
9. Inostics Blood-based Mutation Testing Receives CLIA Certification
10. Breathe Technologies Sleep System Receives FDA Clearance
11. Cochlear Americas Receives FDA Approval for the First and Only Ear Level Accessory for Waterproof Hearing with Cochlear Implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... Gwinnett Family Dental Care , located ... of complete dental care, including general and preventative care as well as restorative and ... team of extensively trained dentists, Dr. Kell Gallaher, Dr. Jon Klevansky, Dr. Jason Klevansky, ...
(Date:7/17/2019)... ... July 17, 2019 , ... Cognition Corporation , ... a new e-book on developing user needs for life science products. ... a small part of the compliance process and the guiding force for product ...
(Date:7/17/2019)... ... 16, 2019 , ... Steven C. Bilt, Chief Executive Officer of Smile Brands ... the dental industry during a panel discussion at Dykema’s 6th Annual Definitive Conference for ... Dallas Hotel in Dallas, Texas. , Bilt co-founded Smile Brands Inc. in 1998 and ...
Breaking Medicine Technology:
(Date:7/17/2019)... ... ... A new study led by researchers at the University of Pittsburgh and published ... the first time that New York’s sepsis protocols are directly responsible for the significant ... infection. It kills more than 275,000 Americans each year and leaves hundreds of thousands ...
(Date:7/17/2019)... ... July 16, 2019 , ... A medical home care program found that ... key to better care for seniors. While this may not sound surprising, a recent ... through its Brandman Research Institute (BRI) uncovered several surprising outcomes based on a simple ...
(Date:7/17/2019)... ... ... Dr. Jonathan Zaidan, MD, FACOG, President of Women’s Excellence discusses a new weight loss ... on Wednesday, July 17ths at 7pm. The show podcast will be available online ... the challenges that women face when it comes to weight loss and any health ...
(Date:7/13/2019)... ... July 13, 2019 , ... ZALO , the ... and innovative rechargeable vibrator and clitoral massager. To view the product and its accompanying ... newest and most advanced, personal massagers to people around the world,” said Mara Epstein, ...
(Date:7/13/2019)... ... July 12, 2019 , ... Ospitek Inc., a leading provider ... platform, Ospitek “View”. Ospitek has partnered with some of the country’s leading surgeons, ... solution made specifically for surgical centers, allowing them to directly engage with patients ...
Breaking Medicine News(10 mins):